BNP PARIBAS ASSET MANAGEMENT Holding S.A. Acquires 186,750 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 25.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 931,048 shares of the company’s stock after acquiring an additional 186,750 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Arcus Biosciences were worth $14,236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of RCUS. Innealta Capital LLC purchased a new stake in Arcus Biosciences in the 2nd quarter valued at about $66,000. Point72 DIFC Ltd purchased a new stake in shares of Arcus Biosciences in the second quarter valued at approximately $83,000. Quest Partners LLC boosted its holdings in shares of Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares during the period. ProShare Advisors LLC grew its stake in Arcus Biosciences by 7.4% in the first quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock worth $205,000 after purchasing an additional 746 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in Arcus Biosciences by 12.1% during the 2nd quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after purchasing an additional 1,467 shares during the period. 92.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on RCUS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. HC Wainwright reissued a “neutral” rating and set a $20.00 target price on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price target for the company. Finally, Barclays lifted their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $34.00.

Arcus Biosciences Price Performance

Shares of RCUS opened at $14.70 on Friday. The company has a 50 day moving average of $16.36 and a two-hundred day moving average of $16.06. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a twelve month low of $13.49 and a twelve month high of $20.31. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -4.67 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same quarter last year, the firm earned ($0.94) EPS. The business’s quarterly revenue was up 50.0% on a year-over-year basis. As a group, analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.